Zepp Health (NYSE:ZEPP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zepp Health (NYSE:ZEPP) from a sell rating to a hold rating in a research note published on Monday,Wall Street Zen reports.

Separately, Fundamental Research set a $53.01 target price on Zepp Health and gave the company a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $53.01.

Zepp Health Stock Up 7.6%

NYSE:ZEPP opened at $4.84 on Monday. The company has a market cap of $71.11 million, a PE ratio of -1.92 and a beta of 1.87. Zepp Health has a twelve month low of $3.85 and a twelve month high of $61.85. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $5.07 and its two-hundred day moving average is $10.43.

Zepp Health (NYSE:ZEPP) last issued its quarterly earnings results on Tuesday, September 1st. The company reported ($0.80) earnings per share (EPS) for the quarter. Zepp Health had a negative net margin of 14.70% and a negative return on equity of 15.64%. The company had revenue of $63.53 million for the quarter.

Insider Transactions at Zepp Health

In other Zepp Health news, CFO Cheng Deng sold 9,836 shares of Zepp Health stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $4.61, for a total transaction of $45,343.96. Following the completion of the sale, the chief financial officer directly owned 114,539 shares in the company, valued at approximately $528,024.79. The trade was a 7.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 36.00% of the company’s stock.

Institutional Trading of Zepp Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. FIL Ltd purchased a new position in shares of Zepp Health during the fourth quarter worth $16,858,000. Millennium Management LLC acquired a new stake in Zepp Health during the 3rd quarter worth about $11,265,000. UBS Group AG grew its position in Zepp Health by 16,412.0% during the 3rd quarter. UBS Group AG now owns 181,302 shares of the company’s stock worth $8,300,000 after purchasing an additional 180,204 shares during the period. Monolith Management Ltd purchased a new position in shares of Zepp Health during the 4th quarter valued at about $3,601,000. Finally, State Street Corp purchased a new position in shares of Zepp Health during the 4th quarter valued at about $3,421,000. Institutional investors and hedge funds own 52.61% of the company’s stock.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.